Abstract：sunitinib achieved encouraging results in the treatment of the chinese advanced renal carcinoma about phase IV clinical studies median progression-free survival (PFS, 14.2∶11 months) and the median overall survival (OS, 30.7∶26.4 months) were better than the sunitinib international phase III clinical study results. But as a new means of adjuvant therapy, it yet lack the higher grade evidence based medicine, clinical researchs at home and abroad are still lacking. Therefore, the study preliminarily summarized the progress of sunitinib-neoadjuvant theray for advanced renal carcinoma.
李延帅, 赵立, 王亚林, 曲楠, 黄晨, 麦海星, 李学超, 陈立军. 舒尼替尼新辅助治疗晚期肾癌患者的研究进展[J]. 微创泌尿外科杂志, 2013, 2(3): 217-219.
Li Yanshuai, Zhao Li, Wang Yalin, Qu Nan, Huang Chen, Mai Haixing, Li Xuechao, Chen Lijun. The research progression of Sunitinib-neoadjuvant therapy for the advanced renal carcinoma. JOURNAL OF MINIMALLY INVASIVE UROLOGY, 2013, 2(3): 217-219.
[1] Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 2006, 24(1): 16-24. [2]Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 2007,356(2):115-124. [3]吴翔, 李学松, 黄立华,等. 舒尼替尼治疗转移性肾癌的疗效和安全性分析:单中心37例总结. 中华泌尿外科杂志, 2011, 32(4): 278-281. [4]Oudard S, Beuselinck B, Decoene J, et al. Sunitinib for the treatment of metastatic renal cell carcinoma. Cancer Treat Rev, 2011,37(3):178-184. [5]Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol, 2007, 178(5):1883-1887. [6]Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol, 2004,171(3):1071-1076. [7]Margulis V, Matin SF, Tannir N, et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol, 2008,180(1):94-98. [8]Stroup SP, Raheem OA, Palazzi KL, et al. Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study. Urology, 2013,81(4):805-811. [9]Kroon BK, de Bruijn R, Prevoo W, et al. Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation. Urology, 2013,81(1):111-115. [10]Peters I, Winkler M, Jüttner B, et al. Neoadjuvant targeted therapy in a primary metastasized renal cell cancer patient leads to down-staging of inferior vena cava thrombus (IVC) enabling a cardiopulmonary bypass-free tumor nephrectomy: a case report. World J Urol, 2012 Sep 30. [Epub ahead of print] [11]von Klot C, Becker JU, Grünwald V, et al. Partial nephrectomy after neoadjuvant administration of sunitinib facilitates preservation of a solitary kidney.Aktuelle Urol, 2012,43(5):337-339. [12]Gorin MA, Ekwenna O, Soloway MS, et al. Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery. Urology, 2012,79(2):e11.
[13]Harshman LC, Yu RJ, Allen GI, et al. Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). Urol Oncol, 2013,31(3):379-385. [14]Bex A, van der Veldt AA, Blank C, et al.Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol, 2009,27(4):533-539. [15]Schrader AJ, Steffens S, Schnoeller TJ, et al. Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy? Int J Urol, 2012,19(10):903-907.
